DIAGNOS Moves Forward with CARA SYSTEM Authorization
In an exciting development, Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), has announced the filing for Saudi Food and Drug Administration authorization of its innovative CARA SYSTEM. This system is a machine-learning-enabled medical device, leveraging Artificial Intelligence (AI) to enhance healthcare.
Understanding the CARA SYSTEM
The CARA SYSTEM is specifically designed to support healthcare professionals in processing and analyzing fundus images effectively. Its primary purpose is the early detection of conditions such as diabetic retinopathy, age-related macular degeneration, and hypertensive retinopathy. By embracing AI, DIAGNOS aims to improve diagnostic accuracy, streamline workflows, and promote better patient outcomes on a global scale.
A Leap in Medical Device Marketing
With this significant filing, DIAGNOS is set to upgrade its existing Medical Device Marketing Device Authorization. The upgrade will not only include the early detection of diabetic retinopathy and age-related macular degeneration but will also encompass hypertensive retinopathy in the future. This strategic move highlights the corporation's commitment to advancing eye health solutions.
Commitment to Revolutionizing Eye Health
André Larente, CEO of DIAGNOS, expressed a firm commitment to transforming eye health using cutting-edge AI technologies. He pointed out that statistics from the International Diabetic Federation reveal a concerning prevalence of diabetes among adults in Saudi Arabia, which stands at 17.7%. This translates to over 4 million individuals at risk of some level of vision loss. The CARA SYSTEM has the potential to effectively triage this population, working to prevent lasting vision impairment stemming from diabetes complications.
Partnership with Kanhoor Medical
DIAGNOS is excited about its collaboration with Kanhoor Medical, who will act as its authorized representative within the Saudi Arabian market. This partnership is crucial for navigating government-related business initiatives, representing an important growth phase for DIAGNOS.
About Kanhoor Medical
Kanhoor Medical, located in Riyadh, specializes in delivering technological solutions tailored for the healthcare sector. Their focus is on developing innovative medical software that enhances operational efficiency within healthcare institutions. By aligning with regulatory standards, Kanhoor ensures compliance and high-quality solutions in the healthcare industry.
About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to the early detection of critical health issues, utilizing its FLAIRE Artificial Intelligence platform. FLAIRE facilitates the rapid development and modification of applications such as CARA (Computer Assisted Retina Analysis). CARA employs advanced image enhancement algorithms to deliver sharper, clearer retinal images, making it a cost-effective solution for real-time patient screening.
Frequently Asked Questions
What is the purpose of DIAGNOS's CARA SYSTEM?
The CARA SYSTEM is designed to assist healthcare professionals in identifying and analyzing retinal diseases, aiming for early detection and improved patient outcomes.
How does the CARA SYSTEM utilize AI?
The CARA SYSTEM leverages machine learning to enhance diagnostic accuracy and streamline workflows for healthcare providers.
Why is the Saudi FDA authorization important?
Obtaining Saudi FDA authorization will allow DIAGNOS to market the CARA SYSTEM in Saudi Arabia, expanding its reach and impact on eye health solutions.
What health issues does the CARA SYSTEM address?
The CARA SYSTEM targets diabetic retinopathy, age-related macular degeneration, and hypertensive retinopathy.
What role does Kanhoor Medical play in this process?
Kanhoor Medical is DIAGNOS's authorized representative in Saudi Arabia, assisting with regulatory compliance and market entry initiatives.
